139 related articles for article (PubMed ID: 20078248)
1. Investigational therapies for non-muscle invasive bladder cancer.
Smaldone MC; Casella DP; Welchons DR; Gingrich JR
Expert Opin Investig Drugs; 2010 Mar; 19(3):371-83. PubMed ID: 20078248
[TBL] [Abstract][Full Text] [Related]
2. Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer.
Smaldone MC; Gayed BA; Tomaszewski JJ; Gingrich JR
Minerva Urol Nefrol; 2009 Jun; 61(2):71-89. PubMed ID: 19451890
[TBL] [Abstract][Full Text] [Related]
3. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
Turker P; Turkeri L
Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
[TBL] [Abstract][Full Text] [Related]
4. Intravesical therapy for bladder cancer.
Williams SK; Hoenig DM; Ghavamian R; Soloway M
Expert Opin Pharmacother; 2010 Apr; 11(6):947-58. PubMed ID: 20205607
[TBL] [Abstract][Full Text] [Related]
5. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
6. Current advances in BCG-unresponsive non-muscle invasive bladder cancer.
Tse J; Singla N; Ghandour R; Lotan Y; Margulis V
Expert Opin Investig Drugs; 2019 Sep; 28(9):757-770. PubMed ID: 31412742
[No Abstract] [Full Text] [Related]
7. Salvage therapeutic strategies for bacillus Calmette-Guerin failure.
Hassler MR; Shariat SF; Soria F
Curr Opin Urol; 2019 May; 29(3):239-246. PubMed ID: 30762670
[TBL] [Abstract][Full Text] [Related]
8. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.
Gontero P; Bohle A; Malmstrom PU; O'Donnell MA; Oderda M; Sylvester R; Witjes F
Eur Urol; 2010 Mar; 57(3):410-29. PubMed ID: 19969411
[TBL] [Abstract][Full Text] [Related]
9. Failure of Bacillus Calmette-Guérin therapy in non-muscle-invasive bladder cancer: Definition and treatment options.
Gual Frau J; Palou J; Rodríguez O; Parada R; Breda A; Villavicencio H
Arch Esp Urol; 2016 Sep; 69(7):423-33. PubMed ID: 27617552
[TBL] [Abstract][Full Text] [Related]
10. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
[TBL] [Abstract][Full Text] [Related]
11. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
12. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
13. Tackling non-muscle invasive bladder cancer in the clinic.
Woldu SL; Şanli Ö; Lotan Y
Expert Rev Anticancer Ther; 2017 May; 17(5):467-480. PubMed ID: 28359179
[TBL] [Abstract][Full Text] [Related]
14. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
15. Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG.
Barlow LJ; Seager CM; Benson MC; McKiernan JM
Urol Oncol; 2010; 28(1):108-11. PubMed ID: 20123359
[TBL] [Abstract][Full Text] [Related]
16. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
[TBL] [Abstract][Full Text] [Related]
17. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis.
Kamat AM; Lerner SP; O'Donnell M; Georgieva MV; Yang M; Inman BA; Kassouf W; Boorjian SA; Tyson MD; Kulkarni GS; Chang SS; Konety BR; Svatek RS; Balar A; Witjes JA
Eur Urol Oncol; 2020 Jun; 3(3):318-340. PubMed ID: 32201133
[TBL] [Abstract][Full Text] [Related]
18. Intravesical therapy for bladder cancer.
Patel SG; Cohen A; Weiner AB; Steinberg GD
Expert Opin Pharmacother; 2015 Apr; 16(6):889-901. PubMed ID: 25773220
[TBL] [Abstract][Full Text] [Related]
19. Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
Yates DR; Brausi MA; Catto JW; Dalbagni G; Rouprêt M; Shariat SF; Sylvester RJ; Witjes JA; Zlotta AR; Palou-Redorta J
Eur Urol; 2012 Dec; 62(6):1088-96. PubMed ID: 22959049
[TBL] [Abstract][Full Text] [Related]
20. Systemic anti-CTLA-4 and intravesical Bacille-Calmette-Guerin therapy in non-muscle invasive bladder cancer: Is there a rationale of synergism?
Fahmy O; Khairul-Asri MG; Stenzl A; Gakis G
Med Hypotheses; 2016 Jul; 92():57-8. PubMed ID: 27241256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]